Cargando…

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy

BACKGROUND: The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curative. Chime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tongjuan, Zhang, Yuanyuan, Peng, Dan, Mao, Xia, Zhou, Xiaoxi, Zhou, Jianfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383265/ https://www.ncbi.nlm.nih.gov/pubmed/30791947 http://dx.doi.org/10.1186/s40425-019-0529-9

Ejemplares similares

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
por: Li, Tongjuan, et al.
Publicado: (2020)

Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy
por: Li, Tongjuan, et al.
Publicado: (2020)

Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia
por: Zhou, Lanlan, et al.
Publicado: (2022)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report
por: Chen, Liting, et al.
Publicado: (2022)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Advances in Universal CAR-T Cell Therapy
por: Lin, Haolong, et al.
Publicado: (2021)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

CAR T-Cell Therapy for Large B-Cell Lymphoma
por: Alencar, Maritza C.
Publicado: (2019)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

CAR-T Cell Therapy in Large B Cell Lymphoma
por: Testa, Ugo, et al.
Publicado: (2023)

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
por: Kenkel, Troy J., et al.
Publicado: (2023)

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report
por: Liu, Wanying, et al.
Publicado: (2022)

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
por: Chen, Liting, et al.
Publicado: (2020)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
por: Liu, Ying, et al.
Publicado: (2022)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
por: McDermott, Kathleen, et al.
Publicado: (2019)

Recent advances in CAR T-cell therapy for lymphoma in China
por: Che, Yuxuan, et al.
Publicado: (2023)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
por: Li, Chunrui, et al.
Publicado: (2021)

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy
por: Lekakis, Lazaros J., et al.
Publicado: (2019)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
por: Xu, Xueer, et al.
Publicado: (2023)

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
por: Dai, Hai-ping, et al.
Publicado: (2022)

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
por: King, Amber C., et al.
Publicado: (2019)

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?
por: Saifi, Omran, et al.
Publicado: (2020)

Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
por: Ladbury, Colton, et al.
Publicado: (2023)

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
por: Mc Laughlin, Anna M., et al.
Publicado: (2023)

Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy
por: Linguanti, Flavia, et al.
Publicado: (2022)

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
por: Paillassa, Jérôme, et al.
Publicado: (2021)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
por: Crees, Zachary D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ta835cpop51ve0tf7rem8sfkd